BioNTech SE

BNTX

Company Profile

  • Business description

    BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

  • Contact

    An der Goldgrube 12
    MainzRPD-55131
    DEU

    T: +49 613190840

    E: [email protected]

    https://www.biontech.de

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6,772

Stocks News & Analysis

stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks

Could merger breathe new life into struggling ASX asset manager?

Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,815.305.00-0.06%
CAC 407,793.6435.65-0.46%
DAX 4024,059.83195.48-0.81%
Dow JONES (US)44,434.7363.220.14%
FTSE 1008,981.6240.500.45%
HKSE24,203.3263.750.26%
NASDAQ20,544.9040.62-0.20%
Nikkei 22539,459.62110.06-0.28%
NZX 50 Index12,678.697.99-0.06%
S&P 5006,251.738.02-0.13%
S&P/ASX 2008,570.409.70-0.11%
SSE Composite Index3,519.659.470.27%

Market Movers